Genetic Determinants of Lung Cancer Survival

The most effective treatment for lung cancer needs to be offered to the right patients at the right time.

The Epidemiology and Genetics of Lung Cancer Research Program's study on the genetic determinants of lung cancer will validate comprehensive and clinical models that accurately predict treatment outcomes and survival based on genomic markers in patients and in their tumors.

These models will be implemented as an easy-to-use tool for assisting patient- and tumor-specific treatment selection and facilitating communication among researchers and care providers.

More specifically, our goal is to build comprehensive and clinically useful models to assist patient-specific treatment selection and to predict therapy responses and survival endpoints, weighing in host and tumor markers to the established predictors.

We have explored such innovative approaches as systems biology and deep nucleic acid sequencing to effectively identify new and meaningful predictive biomarkers and potential therapeutic targets.

Research significance

The significance of this study can be summarized in three levels:

  • The first is lung cancer, the deadly disease under study that has challenged the world for decades in medicine and public health
  • The second is the goal to develop clinically useful models to accurately predict therapy responses and survival endpoints, which could assist treatment decision-making for optimal results and proactively prepare effective management for expected adverse effects
  • The third is the specific aims that are designed to rigorously validate highly promising genomic markers through independent data sets from multiple institutions, provide answers to the relative impact of these markers on the short- and long-term outcomes of lung cancer patients, and produce a Web-based tool accessible to researchers, clinicians and patients

Select related publications

  • Sun Z, Wang L, Eckloff BW, Deng B, Wang Y, Wampfler JA, Jang J, Wieben ED, Jen J, You M, Yang P. Conserved recurrent gene mutations correlate with pathway deregulation and clinical outcomes of lung adenocarcinoma in never-smokers. BMC Med Genomics. 2014;7:32. PMID:24894543; PMCID: PMC4060138.
  • Deng B, Cassivi SD, de Andrade M, Nichols FC, Trastek VF, Wang Y, Wampfler JA, Stoddard SM, Wigle DA, Shen RK, Allen MS, Deschamps C, Yang P. Clinical outcomes and changes in lung function after segmentectomy versus lobectomy for lung cancer cases. J Thorac Cardiovasc Surg. 2014;148(4):1186-1192.e3. PMID: 24746994; PMCID: PMC4169754.
  • Wu X, Wang L, Ye Y, Aakre JA, Pu X, Chang GC, Yang PC, Roth JA, Marks RS, Lippman SM, Chang JY, Lu C, Deschamps C, Su WC, Wang WC, Huang MS, Chang DW, Li Y, Pankratz VS, Minna JD, Hong WK, Hildebrandt MA, Hsiung CA, Yang P. Genome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokers. Cancer Res. 2013;73(13):4028-38. PMID: 23704207; PMCID: PMC3719971.
  • Yang P, Kulig K, Boland JM, Erickson-Johnson MR, Oliveira AM, Wampfler J, Jatoi A, Deschamps C, Marks R, Fortner C, Stoddard S, Nichols F, Molina J, Aubry MC, Tang H, Yi ES. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol. 2012;7(1):90-7. PMID: 22134072; PMCID:PMC3931519.
  • Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MA, Roth JA, Minna JD, Gu J, Lin J, Buch SC, Nukui T, Ramirez Serrano JL, Taron M, Cassidy A, Lu C, Chang JY, Lippman SM, Hong WK, Spitz MR, Romkes M, Yang P. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst. 2011;103(10):817-25. PMID: 21483023;PMCID: PMC3096796.
  • Sun Z, Chen J, Aakre J, Marks RS, Garces YY, Jiang R, Idowu O, Cunningham JM, Liu Y, Pankratz VS, Yang P. Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients. Ann Oncol. 2010;21(10):2011-6. PMID:20439344; PMCID: PMC2946864.
  • Chen J, Jiang R, Garces YI, Jatoi A, Stoddard SM, Sun Z, Marks RS, Liu Y, Yang P. Prognostic factors for limited-stage small cell lung cancer: a study of 284 patients. Lung Cancer. 2010;67(2):221-6. PMID: 19497635; PMCID: PMC2815153.
  • Yang P, Mandrekar SJ, Hillman SH, Allen Ziegler KL, Sun Z, Wampfler JA, Cunningham JM, Sloan JA, Adjei AA, Perez E, Jett JR. Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: an NCCTG-97-24-51 based study. J Thorac Oncol. 2009;4(4):479-85. PMID: 19347979; PMCID: PMC2998042.